BriaCell Therapeutics Corp. | |
Stock Exchange | Other OTC |
EPS |
$0.03 |
Market Cap |
$10.36 M |
Shares Outstanding |
157.83 M |
Public Float |
34.7 M |
BriaCell Therapeutics Corp. | |
Stock Exchange | Frankfurt Stock Exchange |
EPS |
- |
Market Cap |
- |
Shares Outstanding |
157.83 M |
Public Float |
- |
BriaCell Therapeutics Corp. | |
Stock Exchange | Toronto Ventures Stock Exchange |
EPS |
CAD0.04 |
Market Cap |
CAD12.75 M |
Shares Outstanding |
62.02 M |
Public Float |
16.28 M |
Address |
Bellevue Centre West Vancouver British Columbia V7T 2X1 Canada |
Employees | - |
Website | http://www.briacell.com |
Updated | 07/08/2019 |
BriaCell Therapeutics Corp. operates as an immuno-oncology company which engages in the development of immunotherapy treatments for cancer. Its product candidate, BriaVax, is a genetically engineered whole-cell vaccine derived from a human breast cancer cell line. It is used in combination with multiple immune-modulators to powerfully trigger the immune system to recognize and eliminate cancerous cells. |